This GLP-1 cancer headline is being over sold here by breathless doctors who don't understand studies or statistics. This plays into Big Pharma's hands.
The study was an observational database study comparing cancer patients who got GLP-1-type drugs with cancer patients who got DPP-4 inhibitors.
The result could be driven by selection bias: healthier patients, better access to care, different diabetes severity, different obesity treatment, different tumor biology, different tumors, or differences in who gets prescribed which drug.
The press release lumps together different drugs and even includes pramlintide, which is an amylin analog, not a GLP-1 receptor agonist.
This is not proof of any kind whatsoever. It is interesting, that's about it.
EVERY new drug looks this way, with Big Pharma marketing. It takes many years to differentiate signal from noise.